Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  2.50 2.5% 102.50 246,236 09:40:05
Bid Price Offer Price High Price Low Price Open Price
100.00 105.00 102.50 102.00 102.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.07 -13.86 -35.90 58
Last Trade Time Trade Type Trade Size Trade Price Currency
16:40:04 O 50,000 102.00 GBX

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Investors    Reneuron Takeover Rumours

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 100p.
Reneuron Group Plc has a 4 week average price of 100p and a 12 week average price of 72.50p.
The 1 year high share price is 178.50p while the 1 year low share price is currently 72.50p.
There are currently 56,855,705 shares in issue and the average daily traded volume is 260,654 shares. The market capitalisation of Reneuron Group Plc is £58,277,097.63.
jpuff: Rene did a presentation on AJ Bell / Shares Mag webinar a couple of days ago, so this may have stimulated some buying interest. Seemed to go well I thought.
dickbush: By its own admission, the RP product is several years away from possible marketing, even assuming success, although moving to phase 3 testing in a year's time might be enough to bring in deals/bidders. The excitement here is exosomes, the latest hot technology in this sector as evidenced by the prices paid for companies in this area. As always with RENE, investors are left in the dark as to how far they are along with proving its success in carrying other molecules to their targets and improving outcomes for patients. This is two years old
dickbush: Woodford's coming back. I wonder if he is still interested in RENE. They are about 25% of the price he paid, and several years further on in their development "Woodford will manage a familiar set of holdings as part of his new venture, including Immunocore, Oxford Nanopore Technologies Ltd. and Arix Bioscience Plc. Acacia purchased the portfolio for 224 million pounds from Woodford’s now-liquidated fund, and the holdings are now worth around 690 million pounds as many of them benefited from a rally in healthcare stocks during the pandemic." Read more at:
dickbush: Lauders, many thanks for that article. RENE's management has mentioned the possibility of its exosomes being useful in fighting COVID-19, but I thought it was just a try on to boost the share price. Now, if today's announcement of increased options is, heaven forbid, related to this article in the Times of Israel, we may see those option targets realised a lot sooner than 3 years. I can dream...
loafofbread: Schroder UK Public Private Tst plc Agreement for sale of assets 27/01/2021 7:00am UK Regulatory (RNS & others) Woodford Patient Capital (LSE:WPCT) Historical Stock Chart From Jan 2021 to Feb 2021 Click Here for more Woodford Patient Capital Charts. TIDMSUPP RNS Number : 9819M Schroder UK Public Private Tst plc 27 January 2021 Schroder UK Public Private Trust plc (the "Company") Agreement for sale of assets The Company (LSE: SUPP) is pleased to announce that it has signed a sale and purchase agreement for the sale of a basket of seven assets (the "Sale Portfolio") to Rosetta Capital VI, LP (the "Buyer"), an investment fund managed by the UK-based life science venture capital firm Rosetta Capital Limited, for a total acquisition price of GBP49.0 million (the "Transaction"). The Sale Portfolio consists of the Company's entire holdings in Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics and Mereo BioPharma and partial holdings in Inivata, Immunocore and ReNeuron. The agreed acquisition price represents a discount of 22 per cent to the aggregate valuation for those holdings reflected in the Q3 2020 Net Asset Value ("NAV") as at 30 September 2020 (as published on 3 December 2020) or a discount of 19% per cent adjusted for relevant foreign exchange rate changes as of 25 January 2021. The Buyer has also agreed to pay approximately GBP2.9 million to the Company representing the value of certain follow-on investments made by the Company with respect to holdings contained in the Sale Portfolio during January 2021. In total, the Company expects to receive initial proceeds from the Transaction of approximately GBP51.9 million. Furthermore, given the recent news of Immunocore filing for an initial public offering ("IPO"), the Company has agreed with the Buyer an earn-out under which the Company might receive an additional contingent payment of up to GBP5.0 million subject to the Immunocore stake acquired by the Buyer exceeding certain value thresholds at the Buyer's future exit of the investment. The Company had previously agreed to a lock-up period under which it would not sell its entire holding for a period of 6 months from the date of the IPO. The Buyer has agreed to be bound by the restrictions of a lock-up agreement on the same terms as the Company. The Company will remain subject to the lock-up for the proportion of the holding it is retaining. In addition, the Company and the Buyer have agreed to a potential adjustment to the acquisition price in the event of significant changes in value of the listed portfolio companies Mereo BioPharma and ReNeuron on an aggregated basis by the date of completion of the Transaction. The Company does not currently expect the potential acquisition price adjustment, if any, to be significant in the context of the overall transaction. The closing of the Transaction is subject to customary closing conditions. The Company expects the completion to occur in late February or March 2021. The valuation impact of the Transaction is expected to be reflected in the NAV of the Company as at 31 December 2020, which is expected to be announced in April 2021. A significant proportion of the expected proceeds will be used to pay down a meaningful portion of the Company's outstanding debt under its credit facility whereby the current term loan will convert to a revolving credit facility. In addition, the Company intends to use the additional liquidity to support some of its portfolio companies with follow-on capital and further optimise the portfolio composition by selectively investing into new opportunities Tim Creed and Ben Wicks, Portfolio Managers of the Company, jointly commented: "After the announcement of the acquisition of Kymab by Sanofi and the extension of the Company's credit facility by two years, this is the third very positive announcement for the Company so far in 2021. When we assumed the management of the Company's investment portfolio in December 2019, we communicated that our initial focus in the process of repositioning the portfolio would be to reduce the outstanding debt to a sustainable level and put the Company back into a position to support its portfolio companies with follow-on capital and selectively make new investments. The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. Together with the divestiture of Kymab, the Company expects to receive total proceeds of more than GBP115 million by the end of the first half of 2021. Also, we are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company's holdings in delivering sustainable value and positive long-term shareholder returns." Susan Searle, Chair of the Board of the Company, commented: "I am extremely pleased with the progress that Schroders have made since taking over the management of the portfolio. The three announcements made in 2021; the extension of our debt facility, a significant portfolio company cash exit and a portfolio sale put the Company in a solid position from which to grow in 2021. These events reflect the hard work of the team throughout 2020 and I look forward to seeing the team build on this encouraging positive progress in repositioning the Company's portfolio." Enquiries: Schroder Investment Management Limited
the stigologist: Brilliant must read thread on #RENE this RENE now potentially a world leading company in a whole new biotechnology platform technology area Exosomes (Recent Goldman Sachs IPO CDAK Codiak went from $150m to $600m) RENE EV of £40m doesn't do justice to the potential for positive newsflow on this exciting prospect No wonder Professor Sir Chris Evans invested £1m in recent fundraising htTps://
onceaday: I wouldn't disagree with your figures. The only points I would make are (i) I remember reading in the placing document that circa 4M is needed for legacy funding (presumably orderly shutdown of the phase 2b in stroke) and (ii) requirements are less predictable the further out we look. For example, I don"t believe I saw any mention of hRPC partnering in the offer documentation although this was mentioned in relation to exosomes. If the RP ph2a extension study yields acceptable results then RENE may decide to finance the ph3 themselves. This was suggested by Edison. It's such a niche market that they would only require a small selling operation. Financing an hRPC ph3 trial might require further cash unless it comes in from one or more exosome deals. If funding was required, I would expect the fund raise to be on the back of good news and an elevated share price, however. Incidently, I see that Codiak (exosomes) IPO"d and the shares went up 30%.
timbo003: >>>az4hr Sorry, I missed that, so I will try to answer here: If a company is going to issue EIS/VCT qualifying shares it will generally (but not always) have obtained advanced approval from HMRC and your broker should know this. So for example, if you look at the book building announcement yesterday (hit control f to search EIS) you will see that some of the shares qualified for EIS It is not unusual for a company to issue both EIS qualifying and non-qualifying shares in the same fund raising round, this is because EIS cash can only be spent of certain activities (growth capital), it cannot be used for activities such as acquisitions, so if a fund raise is for the purposes of an acquisition and to invest in organic growth, it will not be all EIS qualifying. If a placing opportunity does come along, always ask the broker to confirm if any of the shares qualify for EIS and always stipulate that you only wish to be issued with EIS shares. I would recommend that you check with the broker on a one or two monthly basis to see how the process of obtaining your (necessary) EIS3 certificates is coming along. Obtaining the certificates is a clunky process, it can take a while and can get held up for all sorts of reasons, but if you have someone chase it up on a regular basis, you still generally receive the EIS3 certificate within 3 – 9 months. I would say my success rate for obtaining EIS3 certificates is around 90%. You need the EIS3 certificate to make a claim to HMRC for an income tax refund, without an EIS3 certificate you will definitely not get a refund
onceaday: They are hard to value because of a dependency on the RP trial and exosome research results that are not yet known. From a share price perspective, hard data on either the RP trial or their internal research programs should move the price upwards. I can only see circa £5 being reached if they announce a significant partnering deal. Taking the ex-US jCyte deal and doubling it to take into account US rights would give $500M. That's well in excess of 10x RENE's market cap. How much is the company worth without a deal? I would imagine that the breakup value is at least the current market cap given their IP portfolio and proprietary technology.
s1zematters: supernumerary The previous data has built up a certain amount of expectation. The company recently talked about NHS treatment in a presentation pushed in a you-tube video pumped on this very thread! If the share price yesterday had an element already built in of expectation of widespread future uptake (including nhs) then today's new data questions that somewhat. That was my point!. Shares look forward in this sector by many years, some of the exuberance of the future has been depressed by that data. Moreover, future commercial returns have naturally also been questioned today by some. Temporarily ? Maybe, maybe not! I am not claiming that the treatment in this state would be offered to the NHS as you alluded, that's not only ridiculous, but the genuine "straw man" argument suggesting i was . It's a question mark of expectation of widespread future usage that in part explains the share price collapse today. On one hand You suggest we ignore the steep fall in improvement after 9 months and on the other you assure us that Fosun are happy with the data? It takes a certain sort of narcissistic tendency in owns own investment choices , or maybe just outright reckless abandonment if you choose to discount data you don't like and invent approval from others that you have no way of validating.. Kingpin. That is a very nice share price ride, well done! However,please understand me, i was asked what reason/s do i see the share price falling. My posts have generally been about the impact of that data on the share price going forward until the next data rather than predicting the success or failure long term of the treatment!
Reneuron share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210305 23:33:20